Autres langues Ayala Pharmaceuticals, Inc.

Actions

ADXS

US0076244062

Marché Fermé - OTC Markets Autres places de cotation 21:56:28 09/05/2024			Varia. 5j.	Varia. 1 janv.
0,56 ^USD	-10,40%		+5,56%	-16,04%

16/04	Ayala Pharmaceuticals, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
16/04	Ayala Pharmaceuticals, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations	09/05
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	11/04
North American Morning Briefing : Focus Turns to -2-	04/04
Ayala Pharmaceuticals, Inc. Announces Departure of Roy Golan as Chief Financial Officer, Effective from June 25, 2024	03/04
Andres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, Inc	03/04
North American Morning Briefing : Stocks Set for -2-	28/03
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome	26/03
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	25/03
North American Morning Briefing : Fed's Preferred -2-	29/02
North American Morning Briefing : Nvidia Ignites -2-	22/02
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	20/02
Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid Tumors	20/02
Sector Update: Health Care Stocks Gain Late Afternoon	06/02
Top Midday Gainers	06/02
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	06/02
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals	06/02
Immunome, Inc. entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. for $94.2 million.	06/02
North American Morning Briefing : Stock Futures -2-	27/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Ayala Pharmaceuticals, Inc.

Actions

ADXS

US0076244062

Autres langues

Filtres